1. Generics Bulletin
  2. >>Business
  3. >>Earnings

Return To Growth In Biosimilars A Priority For Biogen

Full-Year Biosimilars Revenue Expected To Be Down Versus 2021

 
• By Chloe Kent

Biogen’s biosimilars business took a hit in Q1 following pricing pressures and negative currency fluctuations, with the company now prioritizing the rebuilding of the segment.

Growth man drawing graph pen
Biogen has listed biosimilars growth as one of its priorities. • Source: Christian Horz / Alamy Stock Photo

Biogen, Inc. has listed driving a potential return to growth in its biosimilars business as one of its key near-term operational priorities, after its biosimilars revenue decreased 5% year-on-year during the first quarter of 2022. Pricing pressure and negative currency impacts took their toll on the segment, as revenue decreased from $205m in Q1 2021 to $194m this year, with the company ultimately expecting a “slight” decline in full-year biosimilars revenue overall compared to 2021.

The firm currently has three biosimilars on the market: Imraldi (adalimumab), Flixabi (infliximab) and Benepali (etanercept), developed through the Samsung Bioepis Co., Ltd. former joint venture with Samsung BioLogics. Flixabi experienced the most substantial YoY hit overall, dropping 16

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Dr Reddy’s Gears For Tariffs Scenario To Ensure No US Supply Disruption

 
• By Anju Ghangurde

Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.

Pfizer Discusses Tariffs Amid International Slump For Oncology Biosimilars Revenue

 
• By Adam Zamecnik

Reflecting conversations across the wider pharmaceutical industry, Pfizer’s earnings call for the first quarter of 2025 focused on the sector’s response to the potential imposition of tariffs by the Trump administration.

Amneal Proud To Be ‘Made In America’ And Ready To Scale Up Its US Manufacturing

 
• By Urtė Fultinavičiūtė

Amneal has set itself apart from competitors who are scrambling to find alternatives if proposed US pharmaceutical tariffs come into place. For the New Jersey-based firm, this is an opportunity to embrace its American identity and open a new chapter of growth.

‘I’ll Be Happy When We Have 40-Plus Assets’ – Sandoz Builds Up Biosimilars

 
• By Dave Wallace

With biosimilars playing an increasingly important role in Sandoz’s business, the firm’s first-quarter results call saw management lay out the latest key developments. Meanwhile, the company also addressed the issue of US tariffs, voicing optimism over both future developments as well as its ability to weather current measures.

More from Business

‘I’ll Be Happy When We Have 40-Plus Assets’ – Sandoz Builds Up Biosimilars

 
• By Dave Wallace

With biosimilars playing an increasingly important role in Sandoz’s business, the firm’s first-quarter results call saw management lay out the latest key developments. Meanwhile, the company also addressed the issue of US tariffs, voicing optimism over both future developments as well as its ability to weather current measures.

Teva To Slash Thousands Of Jobs And Shut More Sites Under $700m Savings Plan

 
• By Dean Rudge

Teva’s plans to generate net savings of $700m by 2027 have been described by the firm as a journey and not a destination, with the suggestion that “this era of cost efficiency, harmonization, frugality will continue.”

Tetris Deal Falls Into Place For UK’s Aspire

 
• By Dave Wallace

Niche generics company Aspire Pharma has struck a deal to acquire a portfolio of products from fellow UK firm Tetris Pharma as it is wound up, paying Tetris parent Arecor £0.5m for UK distribution rights and inventory.